Johnson & Johnson reports data from Phase II prostate cancer trial
In the trial, ERLEADA plus ADT post-radical prostatectomy offered a 100% BCR-free rate at 24 months.
![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/Johnson-Johnson_shutterstock_2290054637-1024x592.jpg)
In the trial, ERLEADA plus ADT post-radical prostatectomy offered a 100% BCR-free rate at 24 months.
The number of pharma companies utilising AI across a medicine’s lifecycle is growing rapidly
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic
Cleerly touts new data for AI cardiovascular software